Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 14, 2005 Chuck Saletta	Controlling the Carnage Relying on perpetually rosy scenarios can kill a portfolio. Value investing offers a way out.
The Motley Fool June 1, 2005 Chuck Saletta	Where Angels Fear to Tread In the right situation, short-term corporate crises can provide superior long-term possibilities. Of course, investing in companies in crisis comes with risk.
The Motley Fool January 19, 2005 Chuck Saletta	Why Value Wins How a disciplined, value-focused approach to investing can turn the odds in your favor.
The Motley Fool January 5, 2005 Chuck Saletta	Sominex for Your Portfolio Investing is a risky activity. Make sure your stocks don't keep you up at night.
The Motley Fool December 14, 2004 Chuck Saletta	Lift Your Lamp for Value It might not seem evident, but there's a strong parallel between Lady Liberty's call and an investor's search for value. Both are looking to accept others' discards.
The Motley Fool January 25, 2005 Stephen D. Simpson	Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Rebuttal There's a reason why Merck's stock is cheap: weak pipeline, weak prospects.
The Motley Fool September 30, 2004 W. D. Crotty	Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment.
The Motley Fool April 21, 2005 Rich Smith	Kinder Morgan's a Winner A winner indeed. If not necessarily in March, then certainly in April. For the rest of this year, pipeline company Kinder Morgan is sticking by its January prediction of better than $4.22 per share in profits.
The Motley Fool October 4, 2004 Mathew Emmert	Got Merck? The pharmaceutical's investors can't seem to catch a break.
The Motley Fool August 1, 2006 Chuck Saletta	Certainly Wrong Because you can't tell the future, you can't know for certain what a company is worth. That's OK, because it means that neither can the market. You can get in the right ballpark, though, by focusing on a company's realistic earnings potential.
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull It's hard to argue with a price this cheap. With a price-to-free cash flow ratio of less than 11, Merck's a steal.
The Motley Fool October 22, 2004 Chuck Saletta	When Crystal Balls Break Proper diversification is one method by which investors can reduce the risk to their portfolio as a whole without significantly compromising their overall expected returns, making it a key tool for any value investor's kit.
The Motley Fool November 18, 2004 Philip Durell	Hunting for Value: Part 1 How can you cultivate solid value investments?
The Motley Fool May 4, 2005 David Meier	Double Your Chances If you find high-yielding stocks at low prices, you may be on your way to beating the market.
The Motley Fool January 9, 2004 Jeff Hwang	RIM Cashes In Share offering may indicate richly valued shares, but also a quest for long-term value.
The Motley Fool March 2, 2005 Chuck Saletta	Why Value Wins How a disciplined, value-focused approach to investing can turn the odds in your favor.
The Motley Fool November 12, 2004 Chuck Saletta	Three Magical Words Margin of safety are the three most important words in value investing.
The Motley Fool January 28, 2005 Philip Durell	Tom Gardner Interviews Philip Durell Tom and the author get together to talk value investing.
The Motley Fool July 30, 2010 Jeremy Phillips	Technically, JDS Uniphase Is a Buy The signal line crossover says you should buy JDS Uniphase right now. But you might not want to listen.
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Rebuttal Yes, Merck is a good company, but investors can still do better.
The Motley Fool October 28, 2005 Chuck Saletta	Lessons of a Lifetime With experience and the right mentor, you can become a market-beating value investor.
The Motley Fool March 23, 2005 Chuck Saletta	Catching the Hot Potatoes Diversification can protect your portfolio from the worst of a company's stumbles.
The Motley Fool January 31, 2005 Stephen D. Simpson	Merck Takes Another Body Blow Loss of exclusivity on major osteoporosis drug could take steam out of the recovery process. Investors in Merck just can't catch a break.
The Motley Fool March 24, 2005 Richards & Smith	Stock Madness 2005: Colgate-Palmolive vs. Kinder Morgan The company that's even older than basketball offers a hefty dividend increase. The other fuels shareholder confidence in "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness.
The Motley Fool April 17, 2007 Ryan Fuhrmann	Clean Bill of Health at Eli Lilly Lilly recorded another solid quarter, but its valuation is a little rich.
The Motley Fool July 20, 2005 Chuck Saletta	Beat the House at Its Own Game Investing will always be risky. You can't eliminate that, but you can tilt the odds in your favor with value investing.
The Motley Fool April 13, 2004 Rich Smith	Kinder Morgan's Wonder Boy With a CEO poster boy for modest compensation, natural gas pipeline giant Kinder Morgan's looking good.
The Motley Fool May 6, 2005 Rich Duprey	A Patient Investor's Guide to Profit One simple virtue can lead you to the right stock at the right price. All too often, investors try to hurry up and climb aboard the latest growth-stock rocket ship only to get burned as it plummets back to Earth.
The Motley Fool May 2, 2005 Dan Bloom	More Struggles for JDS Uniphase Tight competition and declining prices hurt third-quarter earnings at the fiber optic components manufacturer. JDS plans to cut jobs and exit some low-margin businesses.
The Motley Fool April 24, 2006 Robert Aronen	Kinder Morgan Energy on the Move A changing pipeline industry offers this MLP major growth potential. This company offers an opportunity for investors to benefit from America's oil addiction without exposure to volatile commodity prices.
The Motley Fool December 29, 2004 Chuck Saletta	Three Tens for a Twenty Take advantage of opportunities to get discounted pricing on companies.
The Motley Fool November 9, 2005 Chuck Saletta	Cover Your Assets The key point for building a successful value portfolio is determining how to reduce your risk without reducing your expected return along the way. Commission-hungry brokers often sell a strategy known as portfolio insurance, the purchase of derivative securities called "put options," to reduce an investor's risk of loss.
The Motley Fool May 2, 2005 Richard Gibbons	Stock Market Lies A value investor disputes several well-known stock market maxims.
The Motley Fool December 9, 2005 Steven Mallas	Beyond the Numbers JDS Uniphase is a reminder to investors that understanding a company is vital to investing success.
The Motley Fool March 2, 2005 Brant David McLaughlin	Merck's Road to Recovery Merck didn't get to where it is by being shortsighted, and management has no plans to start now. Investors would be wise not to take on an excessively negative attitude toward the company in the wake of some dark news.
The Motley Fool February 23, 2005 Stephen D. Simpson	Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector.
The Motley Fool April 17, 2007 Brian Lawler	Merck Raises the Earnings Roof Shares of Merck soar after it raises 2007 earnings guidance.
The Motley Fool February 21, 2006 Rick Aristotle Munarriz	Biggest Disappointment: Merck In the spirit of the Winter Olympics, here are stock challenges from the publication's writers: Merck is rich in cash, tradition, and potholes.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist?
The Motley Fool April 24, 2006 Robert Aronen	Kinder Morgan's Pipeline of Profits This company operates approximately 43,000 miles of natural gas and petroleum product pipelines in North America and is riding a wave of profits. Is it too late for new investors to go along for the ride?
The Motley Fool January 25, 2006 Tim Hanson	Find the Silver Lining Falling stock prices don't have to be all bad news. While market drops can test your will, it's always best to keep a level head.
The Motley Fool May 27, 2005 Stephen D. Simpson	Once More With Merck Merck has had a busy spring, but are investors any better off?
The Motley Fool October 6, 2005 Chuck Saletta	Waiting on Greatness Waiting is often the hardest part of investing. But it's also usually the most lucrative.
The Motley Fool November 15, 2004 Mathew Emmert	Merck's Silver Lining The government joins the plethora of lawsuit filers, but Merck will survive. Still, the stock remains appropriate for only those investors with a high tolerance for risk and a long-term time horizon.
The Motley Fool July 18, 2005 Mathew Emmert	Don't Worry, Be Wealthy There's enough to worry about without adding your portfolio to the list. Our investments should not keep us up at night, and building a portfolio of companies that will be there when we wake up in the morning is a good way to prevent it.
The Motley Fool July 21, 2005 Stephen D. Simpson	Merck Is No Quack Weighing the pros and cons, it appears that Merck's stock is trading pretty much where it should be. What does make the story a bit more interesting is that robust dividend, which is currently yielding almost 4.8%.
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space.
The Motley Fool April 11, 2007 Billy Fisher	A Replacement for Vioxx at Merck? Drug company has new pain medication in the pipeline. If Arcoxia is approved despite the long odds against it, it could payoff over the long run for Merck shareholders.
The Motley Fool December 7, 2011 Aimee Duffy	7 Stocks to Energize Your Portfolio Now is the time to diversify your portfolio with energy stocks.